Genomic Testing and Tools with Barnaby Balmforth, PhD

Oncology Overdrive

In this episode, host Shikha Jain, MD, speaks with Barnaby Balmforth, PhD, about the evolution of genomics in cancer care, the impact of personalized care tools and more. • Welcome to another exciting episode of Oncology Overdrive :58 • About Balmforth 1:12 • The interview 3:01 • How did you get to where you are today? What drove you to become a leader in this space? 3:45 • What is genomics, and why is genomic analysis important in cancer care? 7:18 • Jain and Balmforth on the evolution of technology and challenges facing genomics and diagnostic testing to achieve personalized care for individual patients. 11:59 • In addition to time, can you speak on the challenge of access for this type of technology? 13:20 • How have you been able to implement “next day” test results and reports of your technology? 17:50 • Jain and Balmforth on how Biofidelity’s technology can transform the delivery of care, as well as its psychological and mental impact. 19:06 • What’s coming down the line for you and Biofidelity? 20:56 • What are your thoughts for when you expand beyond thoracic oncology? What are your long-term visions for other disease sites? 24:19 • Do you have any thoughts on AI and how it may influence genomics in cancer care? 25:51 • If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:37 • How to contact Balmforth 30:37 • Thanks for listening 31:10 Barnaby Balmforth, PhD, is co-founder and CEO of Biofidelity. Barnaby has more than 15 years’ experience in the leadership of multidisciplinary technology development.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [e-mail]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Balmforth can be reached via the Biofidelity website. Disclosures: Jain reports no relevant financial disclosures. Balmforth reports he is an employee of Biofidelity and owns shares in the company.